NEW YORK, June 30, 2017 /PRNewswire/ --
If you want a Stock Review on VRTX, VVUS, XBIT or AXON then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Biotechnology is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Thursday's session 2.95% lower at $127.24 with a total trading volume of 1.37 million shares. Over the last month and the previous three months, the Company's shares have advanced 2.94% and 18.59%, respectively. Additionally, the stock has gained 72.72% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 4.69% and 32.68%, respectively. Moreover, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have a Relative Strength Index (RSI) of 51.33.
On June 08th, 2017, Vertex Pharma's shareholders elected Alan M. Garber, M.D., Ph.D. as an independent member of its Board of Directors. Dr. Garber is Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, a Professor of Public Policy in the Harvard Kennedy School of Government, and a Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health.
On June 23rd, 2017, research firm Needham upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $155 per share. Your complete research report on VRTX can be retrieved for free at:
Shares in Campbell, California headquartered VIVUS Inc. rose 0.83%, ending yesterday's session at $1.21 with a total trading volume of 637,488 shares. The stock has gained 6.14% in the past month, 11.01% in the previous three months, and 5.22% on an YTD basis. The Company's shares are trading 9.46% above their 50-day moving average and 6.16% above their 200-day moving average. Moreover, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 58.56. A free report on VVUS is just a click away at:
On Thursday, Austin, Texas headquartered XBiotech Inc.'s stock saw a decline of 1.39%, to close the day at $4.95. A total volume of 95,330 shares was traded. The Company's shares are trading 40.61% below their 50-day moving average. Additionally, shares of XBiotech, which engages in discovering and developing True Human monoclonal antibodies for treating various diseases, have an RSI of 38.82.
On June 09th, 2017, XBiotech announced that an Independent Data Monitoring Committee (IDMC) has performed its second prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company's novel candidate antibody therapy for the treatment of colorectal cancer. The IDMC had no safety concerns from the unblinded analysis, but recommended the early termination of the study, since the findings were not sufficient to meet efficacy or the threshold for continuation, which involved a prospectively defined acceptance boundary for the interim analysis of less than or equal to p=0.08. Sign up for your complimentary research report on XBIT at:
Shares in London, the UK-based Axovant Sciences Ltd ended the day 1.21% lower at $23.71. A total volume of 209,366 shares was traded. The stock has gained 10.85% in the last one month, 58.70% in the previous three months, and 90.90% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.48% and 48.45%, respectively. Furthermore, shares of Axovant Sciences, which engage in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have an RSI of 53.71.
On June 14th, 2017, research firm Oppenheimer reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $26 a share to $30 a share.
On June 19th, 2017, Axovant Sciences announced that the US Food and Drug Administration has granted Fast Track designation to its investigational drug nelotanserin for the treatment of visual hallucinations disorder in dementia with Lewy bodies. Nelotanserin is a novel 5HT2A inverse agonist being investigated in a Phase-2 double-blind, randomized, placebo-controlled crossover safety study involving more than 20 subjects diagnosed with Lewy body dementia, who experience frequent visual hallucinations. Register for free on DailyStockTracker.com and download the latest research report on AXON at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All